Gilead Sciences Inc beat Wall Street estimates for second-quarter revenue and pr...
) beat Wall Street estimates for second-quarter revenue and profit on Tuesday, driven by higher sales of HIV treatments, and the U.S. drugmaker raised its full-year sales forecast.
The biotechnology company said second-quarter adjusted earnings were $1.82 per share, beating the average analyst estimate by 10 cents, according to IBES data from Refinitiv. Sales of HIV drugs, which accounted for about 71% of total sales, rose to $4.04 billion from $3.67 billion a year ago, driven by $1.12 billion in sales of Biktarvy.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Gilead, Novartis cancer therapies losing patients to experimental treatmentsUnusually high numbers of U.S. lymphoma patients are choosing experimental treat...
Lire la suite »
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatmentsUnusually high numbers of U.S. lymphoma patients are choosing experimental treat...
Lire la suite »
Wall Street eases from record highs as Fed meeting loomsWall Street's main indexes opened below their record highs on Monday, in a ...
Lire la suite »
Boris Johnson's girlfriend is moving into 10 Downing Street with himNew UK Prime Minister Boris Johnson and girlfriend Carrie Symonds will both move into the official Downing Street residence today, a spokeswoman says
Lire la suite »
Wall Street awaits interest rate decision from Federal ReserveRJ Gallo of Federated Investors and Michelle Girard, chief U.S. economist at NatWest Markets, join 'Squawk Box' to discuss the big week ahead in Fed news.
Lire la suite »